14-Feb-2006 - Sigma-Aldrich Chemie GmbH

Sigma-Aldrich strengthens position in RNAi and cell-based assays

Sigma-Aldrich announced that it has signed a series of agreements that expands its position in the areas of RNA Interference (RNAi), gene expression and cell based assays. Sigma-Aldrich and Genospectra, developer of products to support systems biology and drug discovery efforts, have signed several agreements in which Sigma-Aldrich acquires a minority equity stake in Genospectra and is granted access to various Genospectra technologies.

Under the agreed upon terms Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra's technologies for inducible siRNA, a unique nano-particle system for delivery of siRNA and other biomolecules to cells. The companies will participate in a joint program to develop new technology and products in the area of cell-based assays.

Under the terms of the agreements, Sigma-Aldrich will receive licenses to commercialize the inducible siRNA and delivery technologies and distribution rights to the QuantiGene^® product line. Sigma and Genospectra will participate in a joint development program for cell-based assays, particularly to develop novel live cell biosensor assay reagents. These reagents provide real-time data on protein activity and location in living cells, and will make an impact in the High Content Screening and Cell-Based Assay fields.

Facts, background information, dossiers
  • cell based assays
More about Sigma-Aldrich
  • News

    Merck Completes Sigma-Aldrich Acquisition

    Merck announced the completion of its $ 17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry. The completion follows last week’s approval from the European Commission, which was the final antitrust condition required to close the Sigma-Al ... more

    Merck Set to Complete Sigma-Aldrich Acquisition

    Merck announced that following the final approval of the European Commission it is set to complete its $17 billion (€13.1 billion) acquisition of Sigma-Aldrich. The European Commission had granted conditional approval to the acquisition of Sigma-Aldrich on June 15, 2015, subject to the dive ... more

    Merck announces Sigma-Aldrich business sale to Honeywell

    Merck announced that Sigma-Aldrich, the U.S. life science company it plans to acquire, agreed to sell parts of its solvents and inorganics business in Europe to Honeywell in fulfilment of commitments made to the European Union in order to win antitrust approval for its $17 billion acquisiti ... more

  • Companies

    Sigma-Aldrich Chemie GmbH

    more

    Sigma-Aldrich Corp.

    Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high ... more

    Sigma-Aldrich Química, S.A. de C.V.

    Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high ... more